Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with cisplatin and etoposide in extensive-stage small cell lung cancer
NCT00726986Phase 2Terminated
- Start
- Jul 2008
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival at 1 year. Started Jul 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00726986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726986.